Biocon Ltd. is IndiaÍs premier biopharma enterprise focused on innovation to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe. Established in 1978 by Ms Kiran Mazumdar-Shaw, Biocon is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases.
BioconÍs key innovations include worldÍs first Pichia-based recombinant human Insulin, INSUGEN¬, insulin analogue Glargine, BASALOG¬, and IndiaÍs first indigenously produced monoclonal antibody, BioMAb EGFR¬ , for head & neck cancer. INSUPen¬ is a next generation affordable insulin delivery device introduced in India by Biocon.
Continuing on its commitment of affordable innovation, Biocon has delivered its second novel biologic, Itolizumab, a ïfirst in classÍ biologic drug and the worldÍs only anti-CD6 monoclonal antibody. Itolizumab will be commercialized in India as ALZUMAb».
BioconÍs consolidated revenue for FY 13 stands at Rs 25380 million (USD 467 million). Biocon is focused on attaining a size of USD 1 billion by 2018.
Biocon has over 6,700 employees.
Biocon Malaysia:
Biocon is setting up its first overseas manufacturing and research facility at Bio-XCell, Johor, a biotech hub that offers a state-of-the-art biotechnology ecosystem. BioconÍs Malaysia facility will further augment its capabilities to cater to the global needs of diabetic patients for affordable insulin and insulin analogs.
Contact: careers.malaysia@biocon.com
- Company Name:Biocon
(View Trends)
-
Headquarters: (View Map)Bangalore, India
-
Biotechnology
-
5,000 - 10,000 employees
- 277681 Global Rank
- 17152 India
- 139 K Estimated Visits
-
Search50.99%
-
Direct41.65%
-
Referrals3.61%
-
Mail3.22%
-
Social0.53%
-
Display0.00%
-
82.21%
-
4.42%
-
3.50%
-
1.43%
- India 88.2%
- Biotechnology and Pharmaceuticals
- 0 SDKs
- App Url: https://itunes.apple.com/app/biocon/id1250966187
- App Support: http://www.biocon.com/biocon_contact.asp
- Genre: Health & Fitness
- Bundle ID: com.biocon.gerdcalc
- App Size: 13.3 M
- Version: 1.0
- Release Date: June 26th, 2017
- Update Date: June 26th, 2017
Description:
- The GerdQ questionnaire is a simple, self-administered and patient-centred questionnaire comprising six questions.
- First two questions (heartburn, regurgitation) are positive predictors of GERD, where a higher frequency of symptoms is indicated by a higher score.
- Questions 3rd and 4th (epigastric pain and nausea) are negative predictors of GERD and indicate dyspeptic symptoms that reduce the probability of GERD.
- Questions 5th and 6th (sleep disturbances, use of OTC medications) are positive predictors of GERD and also evaluates impact of GERD on daily life.
- For the four positive predictors of GERD, the score of each question ranges from 0 to 3 (0 day is a score of ‘0’, 1 day is ‘1’, 2–3 days is ‘2’, 4–7 days is ‘3’) .
- For the two negative predictors of GERD, a reversed order score ranging from 3 to 0 was followed (0 day is a score of ‘3’, 1 day is ‘2’, 2–3 days is ‘1’, 4–7 days is ‘0’).
- Calculation of likelihood of GERD (addition of scores for response of all questions): Total score of 0 to 2 = 0 % likelihood of GERD; 3 to 7 = 50 % likelihood; 8 to 10 = 79 % likelihood; 11 to 18 = 89 % likelihood.
- Calculation of impact of GERD on quality of life (addition of scores for response of 5th and 6th questions): Score of 0 to 2 = Low impact; 3 to 6 = High impact.
They are headquartered at Bangalore, India, and have 2 advertising & marketing contacts listed on Kochava. Biocon works with Advertising technology companies such as DoubleClick.Net, Google AdSense Custom Search Ads, Google Adsense, Twitter Ads.
